Pavmed prices $4.3m offering

Pavmed (NSDQ:PAVM) today priced an underwritten public offering of 2,415,278 shares of its common stock at $1.80 per share. The New York City-based company said it would grant the offering’s underwriters a 45-day option to buy up to 362,292 additional shares of common stock to cover over-allotments. Pavmed expects to bring in $3.9 million in net proceeds from the offering after discounts and commissions, which it plans to use for working capital and other general corporate purposes. Yesterday, Pavmed registered for a nearly $90 million offering, saying it plans to float the rights to buy up to 14.6 million units. The company said it would issue a single unit for each share of common stock. Each unit is slated to include one common share and a six-year Series Z warrant worth $2.25 per share, redeemable at $3 apiece. Pavmed plans to use the funds it raises from the offering to support its R&D efforts and the development of its current pipeline, according to the prospectus filed with the SEC. Last week, Pavmed cut the exercise price on the Series W warrants, from $2.50 to $2.00 apiece, its second price cut since late last year. Originally exercisable at $5.00 apiece, the company slashed the price in half last December. In November, Pavmed filed a 510(k) application with the FDA for its CarpX device, which is designed to be a minimally-invasive treatment for carpal tunnel syndrome. The post Pavmed prices ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Funding Roundup Wall Street Beat Pavmed Source Type: news

Related Links:

Authors: Yoshida A, Iwatsuki K, Hoshiyama M, Hirata H Abstract BACKGROUND: Several studies on carpal tunnel syndrome have reported pain that exists beyond the median nerve territory of the affected hand. However, the mechanism is unknown. PURPOSE: We investigated the cause of extra-territorial pain by the analysis of clinical assessments and cortical activity using magnetoencephalography. METHODS: To compare patients with and without extra-territorial pain, fourteen patients with carpal tunnel syndrome were assessed using clinical examination, such as patients' profile, paresthesia, physical tests, and psyc...
Source: NeuroRehabilitation - Category: Rehabilitation Tags: NeuroRehabilitation Source Type: research
This study aimed to synthesize the findings of these individual studies across multiple subspecialties of orthopedic surgery to evaluate the potential discrepancy between how much patients believe orthopedic surgeons are reimbursed and the actual reimbursement rate. We performed a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify studies that report findings of patient perceptions of orthopedic surgeon reimbursement for various procedures. Searches were conducted using MEDLINE through PubMed, Embase, and Scopus. Summary estimates of reimbursem...
Source: Southern Medical Journal - Category: General Medicine Tags: South Med J Source Type: research
Publication date: Available online 31 March 2020Source: Journal of OrthopaedicsAuthor(s): Jordan Kaplan, Cameron Roth, Eden Koko, Atlee Melillo, David Fuller, Adam Perry
Source: Journal of Orthopaedics - Category: Orthopaedics Source Type: research
Condition:   Carpal Tunnel Syndrome Intervention:   Other: Median nerve neural mobilization Sponsor:   Universidad Europea de Madrid Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Carpal Tunnel Syndrome;   Ibuprofen;   Pain Management;   Pain, Chronic Intervention:   Drug: Ibuprofen tablets Sponsor:   Universidad Europea de Madrid Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Carpal Tunnel Syndrome | Funding | Grants | Sports Medicine